Caughey Aaron B, Parer Julian T
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco 94143-0550, USA.
Am J Obstet Gynecol. 2002 Jun;186(6):1221-6; discussion 1226-9. doi: 10.1067/mob.2002.123742.
The objective was to review the evidence regarding multiple versus single courses of antenatal corticosteroids (ACS), devise dosing regimens based on this evidence, and then, by using decision analysis, compare 5 ACS regimens: (1) single course, (2) weekly courses, (3) every-other-week dosing, (4) every-other-week dosing with no more than 2 courses, and (5) an every-other-week dosing regimen with no third courses after 30 weeks and no second course after 32 weeks.
The literature was examined for evidence regarding a dose response of the benefits and detriments of ACS. A decision analytic model was designed by using odds ratios, risks of morbidity and mortality, and birth rates from the literature. Mathematic modeling, based on data in the literature, was used to estimate the number of patients who would present at risk for preterm delivery and at what gestational age they would subsequently be delivered. A sensitivity analysis was performed to account for uncertainties in the data.
Of approximately 4 million annual births in the United States, a conservative estimate of 138,000 patients will present between 24 and 34 weeks of gestation at risk for preterm delivery, with 91,915 deliveries. If the 5 different dosing regimens are applied to these patients, strategy 1, the single course of ACS, would result in 30,232 cases of respiratory distress syndrome (RDS) and 4032 neonatal deaths. Three of the other dosing regimens (2, 3, and 5) would all decrease the number of cases of RDS but would concomitantly increase neonatal deaths. Only dosing regimen 4 would decrease the cases of RDS by 2187 without increasing the number of neonatal deaths.
There is evidence that there may be a decrease in the incidence of RDS secondary to the use of multiple doses of ACS; however, a concomitant increase in neonatal deaths may also occur. On the basis of our results, we recommend the following: (1) all fetuses between 24 and 34 weeks' gestation at risk for preterm delivery should be given the first course, (2) if there is a persisting risk of preterm delivery subsequent to this, the next course should be given 2 weeks later, and (3) no more than 2 courses should be given. These recommendations need to be examined in a randomized, controlled trial.
回顾关于多疗程与单疗程产前糖皮质激素(ACS)的证据,基于该证据制定给药方案,然后通过决策分析比较5种ACS给药方案:(1)单疗程;(2)每周疗程;(3)每隔一周给药;(4)每隔一周给药且不超过2个疗程;(5)30周后无第三个疗程且32周后无第二个疗程的每隔一周给药方案。
查阅文献以获取关于ACS利弊剂量反应的证据。通过使用文献中的优势比、发病和死亡率风险以及出生率设计了一个决策分析模型。基于文献数据进行数学建模,以估计有早产风险的患者数量以及他们随后将在什么孕周分娩。进行敏感性分析以考虑数据中的不确定性。
在美国每年约400万例分娩中,保守估计有138,000例患者在妊娠24至34周时存在早产风险,其中91,915例分娩。如果将这5种不同的给药方案应用于这些患者,方案1,即单疗程ACS,将导致30,232例呼吸窘迫综合征(RDS)和4032例新生儿死亡。其他三种给药方案(2、3和5)都会减少RDS病例数,但会同时增加新生儿死亡数。只有给药方案4会使RDS病例数减少2187例且不增加新生儿死亡数。
有证据表明,多剂量使用ACS可能会降低RDS的发生率;然而,也可能会同时增加新生儿死亡数。基于我们的结果,我们建议如下:(1)所有妊娠24至34周有早产风险的胎儿都应给予第一个疗程;(2)如果在此之后仍有持续的早产风险,下一个疗程应在2周后给予;(3)给药不超过2个疗程。这些建议需要在随机对照试验中进行检验。